DESIGN, FORMULATION AND OPTIMIZATION OF METHOTREXATELOADED BUCCAL FILMS FOR ORAL CANCER

AbstractOral squamous cell carcinoma is commonly managed with surgery, radiotherapy, and systemic therapy. Local drug-delivery systems may offer an additional approach by maintaining drug contact with the oral mucosa. Methotrexate (MTX) is an antimetabolite anticancer drug; however, its formulation may be challenging because of its physicochemical properties. This study aimed to prepare a methotrexate–β-cyclodextrin (MTX–β-CD) inclusion complex and incorporate it into mucoadhesive buccal films, followed by formulation, evaluation, and selection of a candidate formulation. The inclusion complex was prepared by kneading at a 1:1 molar ratio. Phase-solubility analysis, Fourier-transform infrared spectroscopy (FTIR), differential scanning calorimetry (DSC), and X-ray diffraction (XRD) were used for characterization. Films were prepared by solvent casting using HPMC E15 and sodium carboxymethylcellulose (Na CMC), with PEG 400 as the plasticizer and mannitol as an excipient. A 2² factorial design with three centre-point formulations was used to examine the effects of polymer concentrations on mucoadhesive strength, folding endurance, and drug release. The phase-solubility study showed a linear AL-type profile (R² = 0.9997). The inclusion complex had a practical yield of 91.42 ± 1.01% and a drug content of 92.59 ± 1.04%. Across formulations F1–F7, mucoadhesive strength ranged from 0.180 ± 0.002 to 0.312 ± 0.002 N, folding endurance from 226 ± 3 to 288 ± 2 folds, swelling index from 28.9 ± 0.3% to 37.7 ± 0.3%, and drug release at 30 min from 77.9% to 96.2%. Formulation F2 (300 mg HPMC E15 and 100 mg Na CMC) was selected as the candidate formulation based on an overall balance of adhesion, flexibility, and drug release. It showed a mucoadhesive strength of 0.237 N, folding endurance of 254 ± 2 folds, and drug release of 89.8% at 30 min. The optimized film showed concentration-dependent cytotoxicity against SCC-9 oral squamous cell carcinoma cells, with a reported IC₅₀ of 74.40 µg/mL, compared with 53.70 µg/mL for 5-fluorouracil. One-month stability observations showed only minor changes in the measured parameters. These findings support further investigation of MTX–β-CD buccal films; additional validation and in-vivo studies are required before therapeutic conclusions can be drawn.

Authors

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-11-18
DOI
https://doi.org/10.5281/zenodo.24330715
Primary Topic
Advanced Drug Delivery Systems
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

DESIGN, FORMULATION AND OPTIMIZATION OF METHOTREXATELOADED BUCCAL FILMS FOR ORAL CANCER

Rashmi Surve, Reshma Sawant, Suraj Gawade, Neha Shivathaya et al.
Zenodo (CERN European Organization for Nuclear Research)
Advanced Drug Delivery Systems
article

DESIGN, FORMULATION AND OPTIMIZATION OF METHOTREXATELOADED BUCCAL FILMS FOR ORAL CANCER

Rashmi Surve, Reshma Sawant, Suraj Gawade, Neha Shivathaya, Seema Pargannavar
article en

Abstract

AbstractOral squamous cell carcinoma is commonly managed with surgery, radiotherapy, and systemic therapy. Local drug-delivery systems may offer an additional approach by maintaining drug contact with the oral mucosa. Methotrexate (MTX) is an antimetabolite anticancer drug; however, its formulation may be challenging because of its physicochemical properties. This study aimed to prepare a methotrexate–β-cyclodextrin (MTX–β-CD) inclusion complex and incorporate it into mucoadhesive buccal films, followed by formulation, evaluation, and selection of a candidate formulation. The inclusion complex was prepared by kneading at a 1:1 molar ratio. Phase-solubility analysis, Fourier-transform infrared spectroscopy (FTIR), differential scanning calorimetry (DSC), and X-ray diffraction (XRD) were used for characterization. Films were prepared by solvent casting using HPMC E15 and sodium carboxymethylcellulose (Na CMC), with PEG 400 as the plasticizer and mannitol as an excipient. A 2² factorial design with three centre-point formulations was used to examine the effects of polymer concentrations on mucoadhesive strength, folding endurance, and drug release. The phase-solubility study showed a linear AL-type profile (R² = 0.9997). The inclusion complex had a practical yield of 91.42 ± 1.01% and a drug content of 92.59 ± 1.04%. Across formulations F1–F7, mucoadhesive strength ranged from 0.180 ± 0.002 to 0.312 ± 0.002 N, folding endurance from 226 ± 3 to 288 ± 2 folds, swelling index from 28.9 ± 0.3% to 37.7 ± 0.3%, and drug release at 30 min from 77.9% to 96.2%. Formulation F2 (300 mg HPMC E15 and 100 mg Na CMC) was selected as the candidate formulation based on an overall balance of adhesion, flexibility, and drug release. It showed a mucoadhesive strength of 0.237 N, folding endurance of 254 ± 2 folds, and drug release of 89.8% at 30 min. The optimized film showed concentration-dependent cytotoxicity against SCC-9 oral squamous cell carcinoma cells, with a reported IC₅₀ of 74.40 µg/mL, compared with 53.70 µg/mL for 5-fluorouracil. One-month stability observations showed only minor changes in the measured parameters. These findings support further investigation of MTX–β-CD buccal films; additional validation and in-vivo studies are required before therapeutic conclusions can be drawn.

Zenodo (CERN European Organization for Nuclear Research)
Good health and well-being
Advanced Drug Delivery Systems
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon